Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Chun Hsu

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
BMC Gastroenterology|May 9, 2021
Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective studyHsu-Heng Yen, Pei-Yuan Su, I-L Ing Liu, et al.
Hepatology International|September 25, 2015
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in TaiwanChia-Chi Wang, Chih-Lin Lin, Tsai-Yuan Hsieh, et al.
Frontiers in Neuroimaging|November 10, 2025
A Bayesian deep segmentation framework for glioblastoma tumor segmentation using follow-up MRIsTanjida Kabir, Kang-Lin Hsieh, Luis Nunez, et al.
Archives of Virology|July 17, 2013
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infectionsMing-Tsung Lin, Yeh-Pin Chou, Tsung-Hui Hu, et al.
Plos One|August 14, 2020
Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world settingHsu-Heng Yen, Pei-Yuan Su, Ya-Huei Zeng, et al.
Cancers|October 26, 2024
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching AnalysisYu-Chun Hsu, Po-Ting Lin, Wei Teng, et al.
American Journal of Cancer Research|December 7, 2023
A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefitChung-Wei Su, Wei Teng, Po-Ting Lin, et al.
PLOS Digital Health|April 10, 2024
Deep learning to predict rapid progression of Alzheimer's disease from pooled clinical trials: A retrospective studyXiaotian Ma, Madison Shyer, Kristofer Harris, et al.
Scientific Reports|April 25, 2025
A pioneering artificial intelligence tool to predict treatment outcomes in ovarian cancer via diagnostic laparoscopyXiaotian Ma, Yu-Chun Hsu, Amma Asare, et al.
American Journal of Cancer Research|April 9, 2024
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitorPo-Ting Lin, Yu-Chun Hsu, Yu-Ting Kao, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
BMC Gastroenterology|May 9, 2021
Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective studyHsu-Heng Yen, Pei-Yuan Su, I-L Ing Liu, et al.
Hepatology International|September 25, 2015
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in TaiwanChia-Chi Wang, Chih-Lin Lin, Tsai-Yuan Hsieh, et al.
Frontiers in Neuroimaging|November 10, 2025
A Bayesian deep segmentation framework for glioblastoma tumor segmentation using follow-up MRIsTanjida Kabir, Kang-Lin Hsieh, Luis Nunez, et al.
Archives of Virology|July 17, 2013
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infectionsMing-Tsung Lin, Yeh-Pin Chou, Tsung-Hui Hu, et al.
Plos One|August 14, 2020
Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world settingHsu-Heng Yen, Pei-Yuan Su, Ya-Huei Zeng, et al.
Cancers|October 26, 2024
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching AnalysisYu-Chun Hsu, Po-Ting Lin, Wei Teng, et al.
American Journal of Cancer Research|December 7, 2023
A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefitChung-Wei Su, Wei Teng, Po-Ting Lin, et al.
PLOS Digital Health|April 10, 2024
Deep learning to predict rapid progression of Alzheimer's disease from pooled clinical trials: A retrospective studyXiaotian Ma, Madison Shyer, Kristofer Harris, et al.
Scientific Reports|April 25, 2025
A pioneering artificial intelligence tool to predict treatment outcomes in ovarian cancer via diagnostic laparoscopyXiaotian Ma, Yu-Chun Hsu, Amma Asare, et al.
American Journal of Cancer Research|April 9, 2024
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitorPo-Ting Lin, Yu-Chun Hsu, Yu-Ting Kao, et al.
Pageof 8